Logo image of JSPR

JASPER THERAPEUTICS INC (JSPR) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:JSPR - US4718712023 - Common Stock

2.05 USD
+0.15 (+7.89%)
Last: 1/7/2026, 8:00:02 PM
1.93 USD
-0.12 (-5.85%)
After Hours: 1/7/2026, 8:00:02 PM
Fundamental Rating

2

Taking everything into account, JSPR scores 2 out of 10 in our fundamental rating. JSPR was compared to 530 industry peers in the Biotechnology industry. While JSPR seems to be doing ok healthwise, there are quite some concerns on its profitability. JSPR has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

JSPR had negative earnings in the past year.
In the past year JSPR has reported a negative cash flow from operations.
In the past 5 years JSPR always reported negative net income.
In the past 5 years JSPR always reported negative operating cash flow.
JSPR Yearly Net Income VS EBIT VS OCF VS FCFJSPR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

JSPR has a worse Return On Assets (-158.38%) than 85.28% of its industry peers.
JSPR has a worse Return On Equity (-786.63%) than 77.74% of its industry peers.
Industry RankSector Rank
ROA -158.38%
ROE -786.63%
ROIC N/A
ROA(3y)-78.35%
ROA(5y)-80.67%
ROE(3y)-100.82%
ROE(5y)-142.02%
ROIC(3y)N/A
ROIC(5y)N/A
JSPR Yearly ROA, ROE, ROICJSPR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for JSPR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
JSPR Yearly Profit, Operating, Gross MarginsJSPR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

JSPR has more shares outstanding than it did 1 year ago.
JSPR has more shares outstanding than it did 5 years ago.
There is no outstanding debt for JSPR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
JSPR Yearly Shares OutstandingJSPR Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 5M 10M 15M
JSPR Yearly Total Debt VS Total AssetsJSPR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

JSPR has an Altman-Z score of -11.40. This is a bad value and indicates that JSPR is not financially healthy and even has some risk of bankruptcy.
JSPR has a Altman-Z score of -11.40. This is in the lower half of the industry: JSPR underperforms 74.53% of its industry peers.
JSPR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -11.4
ROIC/WACCN/A
WACCN/A
JSPR Yearly LT Debt VS Equity VS FCFJSPR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M

2.3 Liquidity

A Current Ratio of 2.59 indicates that JSPR has no problem at all paying its short term obligations.
JSPR has a worse Current ratio (2.59) than 69.43% of its industry peers.
A Quick Ratio of 2.59 indicates that JSPR has no problem at all paying its short term obligations.
JSPR's Quick ratio of 2.59 is on the low side compared to the rest of the industry. JSPR is outperformed by 67.55% of its industry peers.
Industry RankSector Rank
Current Ratio 2.59
Quick Ratio 2.59
JSPR Yearly Current Assets VS Current LiabilitesJSPR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

JSPR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -27.00%.
EPS 1Y (TTM)-27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-0.81%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 13.35% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y4.98%
EPS Next 2Y22.31%
EPS Next 3Y17.48%
EPS Next 5Y13.35%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
JSPR Yearly Revenue VS EstimatesJSPR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2029 2030 2031 2032 50M 100M 150M 200M
JSPR Yearly EPS VS EstimatesJSPR Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -5 -10 -15 -20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

JSPR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for JSPR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
JSPR Price Earnings VS Forward Price EarningsJSPR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
JSPR Per share dataJSPR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

A more expensive valuation may be justified as JSPR's earnings are expected to grow with 17.48% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.31%
EPS Next 3Y17.48%

More info and screens

0

5. Dividend

5.1 Amount

JSPR does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

JASPER THERAPEUTICS INC

NASDAQ:JSPR (1/7/2026, 8:00:02 PM)

After market: 1.93 -0.12 (-5.85%)

2.05

+0.15 (+7.89%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10 2025-11-10/bmo
Earnings (Next)02-25 2026-02-25/amc
Inst Owners73.63%
Inst Owner Change0%
Ins Owners1.05%
Ins Owner Change0.64%
Market Cap57.36M
Revenue(TTM)N/A
Net Income(TTM)-91.02M
Analysts80
Price Target12.92 (530.24%)
Short Float %12.48%
Short Ratio1.88
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-14.74%
Min EPS beat(2)-28.61%
Max EPS beat(2)-0.88%
EPS beat(4)0
Avg EPS beat(4)-15.97%
Min EPS beat(4)-29.09%
Max EPS beat(4)-0.88%
EPS beat(8)3
Avg EPS beat(8)-4.77%
EPS beat(12)6
Avg EPS beat(12)-2.67%
EPS beat(16)9
Avg EPS beat(16)-3.54%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-1.3%
EPS NQ rev (1m)0%
EPS NQ rev (3m)23.07%
EPS NY rev (1m)0%
EPS NY rev (3m)13.52%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.96
P/tB 4.96
EV/EBITDA N/A
EPS(TTM)-6.02
EYN/A
EPS(NY)-2.45
Fwd EYN/A
FCF(TTM)-2.74
FCFYN/A
OCF(TTM)-2.73
OCFYN/A
SpS0
BVpS0.41
TBVpS0.41
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -158.38%
ROE -786.63%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-78.35%
ROA(5y)-80.67%
ROE(3y)-100.82%
ROE(5y)-142.02%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.19%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.59
Quick Ratio 2.59
Altman-Z -11.4
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)41.13%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-0.81%
EPS Next Y4.98%
EPS Next 2Y22.31%
EPS Next 3Y17.48%
EPS Next 5Y13.35%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-35.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-33.33%
EBIT Next 3Y-25.25%
EBIT Next 5YN/A
FCF growth 1Y-58.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-58.45%
OCF growth 3YN/A
OCF growth 5YN/A

JASPER THERAPEUTICS INC / JSPR FAQ

What is the ChartMill fundamental rating of JASPER THERAPEUTICS INC (JSPR) stock?

ChartMill assigns a fundamental rating of 2 / 10 to JSPR.


Can you provide the valuation status for JASPER THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to JASPER THERAPEUTICS INC (JSPR). This can be considered as Overvalued.


Can you provide the profitability details for JASPER THERAPEUTICS INC?

JASPER THERAPEUTICS INC (JSPR) has a profitability rating of 0 / 10.


What is the expected EPS growth for JASPER THERAPEUTICS INC (JSPR) stock?

The Earnings per Share (EPS) of JASPER THERAPEUTICS INC (JSPR) is expected to grow by 4.98% in the next year.